Drug Development

Blog Post

Pfizer Announces Positive Results from Phase 1b Study of PF-06939926 for Treatment of DMD

By Sujatha Gurunathan | June 1, 2020
Blog Post

Orphazyme Announces FDA Fast Track Designation for Development of Arimoclomol for Treatment of ALS

By Sujatha Gurunathan | May 26, 2020
Featured Article

MDA’s 2020 Clinical Scientific Conference Trial News and Updates

By MDA Staff | May 15, 2020
Featured Article

Pompe Disease Treatment Is Moving Forward

By MDA Staff | May 15, 2020
Blog Post

MDA Advocacy in These Uncertain Times

By Mark Fisher | March 19, 2020
Blog Post

NS Pharma Launches Expanded Access Program for Viltolarsen

By Jeanene Swanson | March 9, 2020
Illustration of DNA
Blog Post

FDA Accepts NS Pharma’s NDA for Viltolarsen for the Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | February 26, 2020
Blog Post

MDA’s New Chief Research Officer Sharon Hesterlee Shares Vision for the Future

By Jeanene Swanson | February 21, 2020
Blog Post

Clinical Trial Alert: Expansion Therapeutics Seeks Participants for a Phase 1 DM1 Study

By MDA Staff | February 18, 2020
Blog Post

Clinical Trial Alert: LGMD2I Participants Sought for a Phase 3 Study

By MDA Staff | February 11, 2020